BMS lowers IPO target to $600M

In what analysts see as a test of the paltry IPO market, Bristol-Myers Squibb will sell off part of its Mead Johnson subsidiary for $21 to $24 per share, hoping to bring in $600 million. That's a lot less than it originally expected to raise from Mead Johnson: $1 billion. Report